UPDATE: Sanofi (SNY), Regeneron (REGN) Win New Trial in Amgen (AMGN) Case over Praluent - Bloomberg

October 5, 2017 9:53 AM EDT

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
(Updated - October 5, 2017 10:00 AM EDT)

Sanofi (NYSE: SNY) and Regeneron (NASDAQ: REGN) won a new trial in a case against Amgen (Nasdaq: AMGN) over Praluent after an appeal court said they can raise issues related to the validity of Amgen patents, according to Bloomberg.

The court vacated an order blocking Sanofi from selling Praluent.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, Litigation, Trader Talk